Page header

Recommendation of the President – Influvac (trivalent influenza vaccine (surface antigen), inactivated)

On 7 May 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 62/2026 on the inclusion of the medicinal product Influvac (trivalent influenza vaccine (surface antigen), inactivated) in the reimbursement program for all registered indications as of the date of this decision

Publication in Public Information Bulletin (BIP) >>